Background and objectives: Ferric carboxymaltose (FCM) has been recently introduced for the treatment of anemia. The present study was planned to compare the efficacy, tolerability, and safety of intravenous FCM with intravenous iron sucrose (IS) in the treatment of iron deficiency anemia among pregnant women.
INTRODUCTION
Anemia during pregnancy is a frequently encountered problem all over the world, especially in the developing countries. 1 The most common cause of anemia in pregnancy is iron deficiency. 2 Iron deficiency anemia is accompanied by depleted iron stores and signs of a compromised supply of iron to the tissues. 3 The incidence of iron deficiency anemia is high in developing countries, 4 ,5 mainly because of multiple pregnancies and closely spaced pregnancies due to poor awareness of the global burden. Oral iron is the usual preferred route of therapy, since it is noninvasive and easy to administer. It has its own limitation as it requires good patient compliance and is associated with adverse gastrointestinal side effects. These limitations of oral preparation lead to high variability in patient compliance and response to treatment. Parenteral iron therapy is recommended in patients with poor compliance, intolerance to oral iron preparations, cases of documented malabsorption, and severe anemia. An ideal parenteral preparation should be able to deliver sufficient amount of iron without any adverse effects and should be free from antibody producing compounds.
JSAFOG

Journal of South Asian Federation of Obstetrics and Gynaecology, October-December 2016;8(4):314-318
Iron sucrose (IS) has been used widely for treatment of iron deficiency in pregnant women in 2nd and 3rd trimester. However, its use is limited by the low maximum dosage due to local and systemic side effects in higher doses. 6 In order to avoid these adverse effects, the drug has to be administered in multiple infusions of lower doses less than 200 mg/day. Hence it increases the number of days of admission in the hospital and it becomes an extra burden on the hospital resources.
In view of the limitations of IS, a newer compound ferric carboxymaltose (FCM) is available for the treatment of iron deficiency anemia. It comprises a macromolecular iron-hydroxide complex of polynuclear iron hydroxide tightly bound in a carbohydrate shell. This new complex has a molecular weight of 150,000 Daltons. This design allows for a controlled delivery of iron within the cells of reticulo-endothelial system and hence subsequent delivery to the iron-binding proteins, with a minimal risk of release of large amounts of ionic iron in the serum. This iron preparation can be used intravenously in high doses with up to 1000 mg infused in 1 to 5 minutes with low risk of side effects. Its use is approved in the 2nd and 3rd trimesters of pregnancy. 7 However, there is limited evidence of randomized trials concerning the clinical use of FCM in pregnant women. The aim of our study is, therefore, to compare intravenous (i.v.) FCM with i.v. IS during pregnancy regarding the efficacy, tolerability, and safety profile.
MATERIAlS AnD METHoDS
The present study was conducted in the Department of Obstetrics and Gynecology, KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, Belgaum, Karnataka, India during the period of January 2013 to December 2013. The study design was open-labeled randomized controlled trial with the study conducted from January 2013 to July 2014. A sample size of 305 pregnant women was included in the study. The levels of rise of hemoglobin mentioned in the prior study 8 were used to calculate the minimum sample size of 230. However, a total of 305 patients fulfilled the selection criteria. The inclusion criteria were pregnant women whose hemoglobin is in the range of 7 to 11 gm/dL and women between 16 and 35 weeks period of gestation, while the exclusion criteria were women not willing to participate, other causes of anemia, serious medical complications, and women who have a history or known allergic to parenteral iron infusion. The study was approved by the Institutional Ethics Committee of Jawaharlal Nehru Medical College, Belgaum. Pregnant women fulfilling the selection criteria were briefed about the nature of the study and details of the treatment, and a written informed consent was obtained.
Demographic data, like age, education, qualification, socioeconomic status, were obtained and recorded on predesigned and pretested performa. Patients were interviewed for obstetric history. The study investigators examined the participants for their general health and obstetric parameters. The weight, height of the participants was recorded using standard methodology. A baseline hemoglobin was measured and the total required dose of iron was calculated using the formula: Deficit = (11-Hemoglobin of the patient) × 2.4 × Weight + 500 (storage). Randomization was done by computergenerated random numbers assigning the patients to either group S (IS) or group C (FCM).
Group S -Iron sucrose: Iron sucrose was given in a dose of 200 mg intravenously in 200 mL normal saline over a period of 15 to 20 minutes on alternate days until the required total dose was administered, not exceeding the maximum dose of 1000 mg/week.
Group C -Ferric carboxymaltose: Ferric carboxymaltose was given as per the total required dose of 100 to 200 mg in 50 mL NS, 200 to 500 mg in 100 mL NS over 6 minutes duration, and 500 to 1000 mg in 250 mL NS over 15 minutes duration, not exceeding the maximum dose of 1000 mg/day/week.
All the doses were given in the ward where equipment for cardiopulmonary resuscitation was available. Patients were observed for side effects or anaphylactic reactions. Any minor or major side effects were documented. Hemoglobin test was repeated at the end of 4 weeks interval.
The participants were observed during transfusion for any adverse reaction immediate or late. They were followed up after 4 weeks, for hemoglobin estimation to note the rise in hemoglobin values.
The categorical data was expressed in terms of frequencies and percentages, while continuous data was expressed as mean ± standard deviation (SD). The two groups were compared using chi-square test for categorical data and independent sample t test was used to compare the means of different parameters. A p value of less than or equal to 0.05 was considered as statistically significant.
RESULTS
A total of 305 patients were included in the study and randomized to group C (n = 158) who received iron carboxymaltose transfusion and group S (n = 147) who received IS transfusion. Of the 158 women included in group C, five were lost to follow-up and in group S, of the 147 women, seven lost to follow-up while one woman delivered. Hence the outcome data was available for 153 women in group C and 139 women in group S (Flow Chart 1).
In the present study, the commonest age group was 26 to 30 years in group C comprising 40.52% compared with 21 to 25 years in group S, with 38.85% of the women (p = 0.312) and the mean age of the study population in group C and S was comparable (25.33 ± 3.53 vs 24.85 ± 4.18 years; p = 0.082). The other sociodemographic characteristics of the study population, including occupation (p = 0.303), educational status (p = 0.059), socioeconomic status (p = 0.253), were comparable (Table 1) . Further, the obstetric history including parity (p = 0.078), gestational age at enrolment (p = 0.182), mean period of gestation (p = 0.706), body mass index (p = 0.747), mean body mass index (p = 0.464) were also comparable. On examination, vitals including pulse rate and blood pressure did not differ in both the groups (p > 0.050).
The pretreatment hemoglobin levels were between 7.0 and 9.9 in group C among 93.46% women compared with 92.81% in group S (p = 0.824). The posttreatment hemoglobin levels in 54.9% of the women were found to be 11 gm% or more in group C compared with 56.12% in group S (p = 0.614), and the mean posttreatment hemoglobin levels were comparable in group C and group S (11.59 ± 7.72 vs 11.02 ± 0.75 gm%; p = 0.358). However, significantly higher number of women in group C had increase in hemoglobin levels between 2.0 and 2.5 gm% (56.86%) compared with group S (48.82%) (p = 0.047) ( Table 2 ). The mean increase in hemoglobin levels posttreatment was significantly high in group C (2.27 ± 0.39 gm%) compared with group S (2.17 ± 0.39 gm%) (p = 0.023) ( Table 3) . In group C, 75.16% of the women were found to have increase in hemoglobin percentage between 15 and 30% compared with 85.61% in group S (p = 0.076), and the mean percentage change in hemoglobin levels posttreatment was significantly high in group C (26.54 ± 5.98%) compared with group S (24.99 ± 6.06%) (p = 0.029).
The side effects were noted in 36.64% of the women in group C and 38.13% in group S (p = 0.536) ( Table 4 ). It was observed that significantly higher number of women had pyrexia in group C (8.5%) compared with group S (2.88%) (p = 0.041). Some of the patients had more than one side effect with commonest combination of pyrexia with nausea and headache. Overall, the data from this study is consistent with existing data that intravenous iron carboxymaltose administration in pregnancy is likely to be safe and effective. However, the limitation of the study was that due to the limited financial assistance, blood indices like serum ferritin, transferrin saturation, and other indices for iron deficiency anemia was not feasible in our study. Ideally measuring serum ferritin levels would have been a marker for noting the efficacy of the treatment. Furthermore, the follow-up of patients was done only at the end of 4 weeks. Serial follow-ups at the end of 2, 4, 6, and 8 weeks would have been better in observing the trend in rise of hemoglobin values. Since the duration of our study was short, the follow-up of the neonates and infants was not included in the study.
Flow Chart 1: Consortium diagram
The cost of the FCM drug is relatively high when compared with other available parenteral iron preparations. This high cost of the drug is well compensated by the lesser number of visits and number of days of hospital admission. Further studies including large number of women in a randomized controlled trial along with the long-term follow-up of the neonates would extend the effectiveness, safety, and efficacy of intravenous iron carboxymaltose in the treatment of iron deficiency anemia in pregnancy.
CONCLUSION
Based on the results of this study, it may be concluded that the intravenous iron carboxymaltose is more effective in the treatment of iron deficiency anemia among pregnant women compared with intravenous IS. Further, it is well tolerated in pregnant women as side effects are comparable to that of IS except pyrexia.
